Hanchor-KY (7827) reported revenue of NT$0 for Oct 2026. Revenue for Jan–Oct 2026 was NT$27.7 million (-91.1% year on year).
In Oct 2026, it ranked No. 156 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$0 | — | — |
| Sep 2026 | NT$0 | -100.0% | — |
| Aug 2026 | NT$0 | — | -100.0% |
| Jul 2026 | NT$18.1 million | — | — |
| Jun 2026 | NT$0 | — | — |
| May 2026 | NT$0 | — | -100.0% |
| Apr 2026 | NT$9.5 million | — | — |
| Mar 2026 | NT$0 | — | — |
| Feb 2026 | NT$0 | — | — |
| Jan 2026 | NT$0 | — | — |
| Dec 2025 | NT$0 | — | — |
| Nov 2025 | NT$0 | — | — |
| Oct 2025 | NT$0 | — | -100.0% |
| Sep 2025 | NT$312.2 million | — | — |
| Aug 2025 | NT$0 | — | — |
| Jul 2025 | NT$0 | — | — |
| Jun 2025 | NT$0 | — | — |
| May 2025 | NT$0 | — | — |
| Apr 2025 | NT$0 | — | — |
| Mar 2025 | NT$0 | — | — |
| Feb 2025 | NT$0 | — | — |
| Jan 2025 | NT$0 | — | — |
| Dec 2024 | NT$0 | — | — |
| Nov 2024 | NT$0 | — | — |
| Oct 2024 | NT$0 | — | — |
Jan–Oct 2026 cumulative: NT$27.7 million (-91.1% YoY)
Other Biotech & Medical companies
Compare with peers: Hanchor-KY vs PEC / Hanchor-KY vs Lotus Pharm / Hanchor-KY vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
Company remark (original Chinese)
增減變動差異原因: 係本年為臨床藥品銷貨收入,去年同期則為授權相關履約義務已經達成而認列相關授權收入
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16